Moleculin Biotech, Inc. MBRX
8.66 USD -0.04 (-0.46%)
At closeNov 9, 2026, 4:00 PM EST
8.66 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
8.54 Day range 8.88
3.22 52-week range 253.00
- YTD
- +161.63%
- 1 year
- -29.19%
News
benzinga.com Moleculin Reports 43% And 36% Complete Remission Rates In Annamycin Phase 2/3 Trial For Relapsed Or Refractory AML First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AMLMoleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company")
globenewswire.com Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML
benzinga.com Moleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") today announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20 Filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The…- benzinga.com Moleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company") today announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin…
benzinga.com Moleculin Biotech Announces Preclinical Data Showing Annamycin Antitumor Activity In Pancreatic Cancer Is Immune-Mediated Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
benzinga.com Dow Surges Over 200 Points; Chicago Fed Activity Index Falls In August U.S. stocks rose Monday, led by the Dow’s 200-point gain; communication shares climbed, energy fell, while oil dropped and Greenland stocks surged.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 110.6% to $1.39 during Friday's regular session. Tenon Medical (NASDAQ:TNON) shares rose 69.71% to $8.99. The company's market cap…
benzinga.com HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3 HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $22 to $3.- benzinga.com Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
benzinga.com Moleculin Biotech Stock Is Sinking Friday: What's Going On? Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's regular session. The market value of their outstanding shares is at $1.4 million. SciSparc (NASDAQ:SPRC)…
- benzinga.com Moleculin CEO Highlights Preliminary Unblinded Efficacy Results From First 45 Patients Enrolled In Part A Of Pivotal Phase 2/3 MIRACLE Trial Evaluating Annamycin In R/R AML During Investor Segment Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What
benzinga.com Why is Moleculin Stock Falling Today? Moleculin reports interim Phase 2/3 trial data as Annamycin shows higher remission rates than control in relapsed or refractory acute myeloid leukemia- benzinga.com Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remission Reaches 50%, 57% In Respective Arms Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the Company's
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market session. The company's market cap stands at $5.6 million. Boundless Bio (NASDAQ:BOLD) shares rose 62.85% to…
benzinga.com Moleculin Biotech Enrolls 45th Participant In Its Pivotal Phase 2B/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What…
benzinga.com Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting The poster presentation, titled "Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis," highlighted findings from a pooled analysis across five completed clinical…- benzinga.com Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the analyst consensus estimate of $(1.57) by 125.48 percent. This is a 77.59 percent increase over losses…
benzinga.com Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding Moleculin Biotech nears first MIRACLE trial data unblinding as Annamycin shows higher remission rates in relapsed AML patients.
benzinga.com Moleculin Announces Data From Phase 2B/3 "MIRACLE" Trial Evaluating Annamycin In Combination With Cytarabine Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of careFirst 45-subject data unblinding expected before June 30,…- benzinga.com Moleculin Biotech Announces Publication Of An Abstract At The European Hematology Association Congress That Highlights The Cardiac Safety Profile Of Annamycin The abstract titled, "Cardiac Safety of L-Annamycin Across High Cumulative Anthracycline Exposure: Implications for Relapsed/Refractory AML," will highlight pooled cardiac safety findings from five…
- benzinga.com Moleculin Biotech Announces Significant Advancement In IP Portfolio With Issuance Of Hong Kong Patent Covering Proprietary Method Of Reconstituting Liposomal Annamycin Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseHOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $22 price target.
- benzinga.com Moleculin Biotech Announces 45th Enrollee In Phase2B/3 Trial For Annamycin Plus Cytarabine As A Treatment For Relapsed Or Refractory Acute Myeloid Leukemia This milestone triggers the final phase of preparation for the trial's interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point…
- benzinga.com Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the analyst consensus estimate of $(11.60) by 124.75 percent. This is a 181.73 percent decrease over…
benzinga.com Crude Oil Gains 2%; Walmart Posts Upbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Dow Falls Over 250 Points; US Initial Jobless Claims Decline 
benzinga.com Moleculin Biotech Reports Preliminary Composite Complete Remission Rate Of 40% In Phase 2B/3 Miracle Trial's First 30 Subjects Treated, With Annamycin In Combination With Cytarabine For Refractory To Or Relapsed Acute Myeloid Leukemia After Induction Therapy Preliminary blinded CR rate showed 67% improvement over historical cytarabine responseRoughly 35% of the subjects treated to date represent ventoclax regimen failures.First 45 subjects treated on…- benzinga.com Moleculin Biotech Secures Japan Patent Allowance For Liposomal Annamycin Method Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent Application No. 2021-577862…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Moleculin Biotech Receives New Independent Assessment For Absence Of Cardiotoxicity In Annamycin, 90 Subjects Reviewed To Date – Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials– This next-generation anthracycline demonstrates safety and promising early activity in treating…
- benzinga.com Moleculin Biotech Regains Nasdaq Listing Compliance; Delisting Hearing Canceled As previously disclosed, on May 23, 2025, Moleculin Biotech, Inc. (the "Company") received a letter from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market…
- benzinga.com Moleculin Biotech Data From Phase Clinical Study Of WP1066 Demonstrates Anti-Tumor Immune Responses To Treat Pediatric Recurrent Malignant Brain Tumors Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced positive results from the Emory University physician-sponsored Phase 1 clinical trial conducted at the Aflac…
- benzinga.com HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Raises Price Target to $22 HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and raises the price target from $4 to $22.
- benzinga.com Moleculin Biotech Raises $6.5M From Immediate Exercise Of 1,044,329 Warrants At $6.63 And $6.3219, Issues 2.61M New Warrants At $6.63 Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today…
- benzinga.com Moleculin Biotech Reports 78% Enrollment Toward First Interim Data Unblinding In Pivotal Phase 2B/3 MIRACLE Study Of Annamycin + Cytarabine In r/r AML Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected rangeConsented subjects now across seven countries supporting the expansion of the…
- benzinga.com Moleculin Biotech Partners With CIC biomaGUNE To Preclinically Test Annamycin For Glioblastoma Treatment Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of AnnamycinHOUSTON, Dec. 08, 2025…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Moleculin Announces 1-For-25 Reverse Stock Split, Effective December 1 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session